chemmart alendronate plus d3 and calcium alendronic acid (as sodium) 70 mg/ colecalciferol 140 ug tablets and 1250 mg calcium carbonate tablets composite pack
arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture
alendronate plus d3 and calcium apotex alendronic acid (as sodium) 70 mg/ colecalciferol 140ug tablets and 1250mg calcium carbonate tablets composite pack
arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture
terry white chemists alendronate plus d3 and calcium alendronic acid (as sodium) 70 mg/ colecalciferol 140 ug tablets & 1250 mg calcium carbonate tablets composite pack
arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: hypromellose; magnesium stearate; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture
genrx alendronate plus d3 and calcium alendronic acid (as sodium) 70 mg/ colecalciferol 140 ug tablets and 1250 mg calcium carbonate tablets composite pack
arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture
dronalen plus d-cal alendronic acid 70mg/colecalciferol 140 microgram tablet and 1250mg calcium carbonate tablet composite pack
merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -
fosamax plus d-cal alendronic acid 70mg/colecalciferol 140 microgram tablet and 1250mg calcium carbonate tablet composite pack
merck sharp & dohme (australia) pty ltd - alendronate sodium,calcium carbonate,colecalciferol -
mesasal mesalazine 250 mg enteric coated tablet blister pack
viatris pty ltd - mesalazine, quantity: 250 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; povidone; sodium carbonate; purified talc; titanium dioxide; iron oxide red; colloidal anhydrous silica; calcium stearate; glycine; iron oxide yellow; methacrylic acid copolymer; macrogol 6000; triethyl citrate - indications as at 12 september 1990: treatment of acute inflammatory large bowel disease. maintenance therapy of crohns colitis and ulcerative colitis in patients sensitive to sulfasalazine.
palexia sr tapentadol (as hydrochloride) 250 mg sustained release tablet blister pack
seqirus pty ltd - tapentadol hydrochloride, quantity: 291.2 mg (equivalent: tapentadol, qty 250 mg) - tablet, modified release - excipient ingredients: iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; macrogol 6000; lactose monohydrate; hypromellose; magnesium stearate; purified talc; iron oxide black; titanium dioxide; colloidal anhydrous silica - palexia sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. palexia sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. palexia sr is not indicated as an as-needed (prn) analgesia.
lithium carbonate tablet lithium carbonate capsule, gelatin coated lithium solution
hikma pharmaceuticals usa inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate 300 mg - lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar i disorder: lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet or capsule or lithium citrate products [see adverse reactions (6)]. risk summary: lithium may cause harm when administered to a pregnant woman. early voluntary reports to international birth registries suggested an increase in cardiovascular malformations, especially for ebstein’s anomaly, with first trimester use of lithium. subsequent case-control and cohort studies indicate that the increased risk for cardiac malformations is likely to be small; however, the data are insufficient to establish a drug-associated risk. there are concerns for maternal and/or neonatal lithium toxicity during late pregnancy and the postpartum period [see clinical considerations] . published animal developmental and toxicity studies in mice and rats report an increased incidence of fetal mortality, decreas
lithium carbonate tablet
sun pharmaceutical industries, inc. - lithium carbonate (unii: 2bmd2gna4v) (lithium cation - unii:8h8z5uer66) - lithium carbonate 300 mg - lithium is a mood-stabilizing agent indicated as monotherapy for the treatment of bipolar i disorder: - treatment of acute manic and mixed episodes in patients 7 years and older [see clinical studies (14)] - maintenance treatment in patients 7 years and older [see clinical studies (14)] lithium is contraindicated in patients with known hypersensitivity to any inactive ingredient in the lithium carbonate tablet [see adverse reactions (6)] . risk summary lithium may cause harm when administered to a pregnant woman. early voluntary reports to international birth registries suggested an increase in cardiovascular malformations, especially for ebstein’s anomaly, with first trimester use of lithium. subsequent case-control and cohort studies indicate that the increased risk for cardiac malformations is likely to be small; however, the data are insufficient to establish a drug-associated risk. there are concerns for maternal and/or neonatal lithium toxicity during late pregnancy and the postpartum period [see cl